在稳定的COPD患者中,umeclidinium/vilanterol双重支气管扩展剂治疗对肺功能和炎症反应的影响
Rongbin Jiang1, Weijie Zhan2, Xiaoyun Jian1
1Department of Respiratory Medicine, The Third Hospital of Hebei Medical University , No .139 Ziqiang Road,P.R. China, Shijiazhuang, 050000, Hebei Province, China.
Scientific reports
|November 13, 2025
概括
与tiotropium或budesonide/formoterol相比,umeclidinium/vilanterol (UMEC/VI) 双重支气管扩展剂治疗改善了COPD患者的肺功能,并减少了COPD患者的恶化. 在这项观察性研究中,UMEC/VI显示出优异的结果和更好的安全概况.
科学领域:
- 呼吸系统医学 呼吸系统医学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 慢性阻塞性肺病 (COPD) 是一个重大的全球健康挑战,需要优化治疗策略.
- 目前的指导方针建议针对COPD进行个性化支气管扩展剂治疗,但现实世界的比较有效性数据很少,特别是在中国人群中.
- 有限的比较数据存在于umeclidinium/vilanterol (UMEC/VI) 双重支气管扩展剂治疗与其他标准的COPD治疗.
研究的目的:
- 为了比较UMEC/VI双重支气管扩展剂治疗与tiotropium单一治疗和budesonide/formoterol联合治疗的实际有效性和安全性.
- 在稳定的COPD患者中,评估肺功能 (FEV1),功能能力,症状负担,炎症标志物和恶化率在12个月内发生的变化.
- 评估不同治疗方案的安全性和耐受性.
主要方法:
- 一项前性观察队列研究,涉及171名稳定的COPD患者在12个月内.
- 根据临床决定,患者被分配给UMEC/VI (n=57),tiotropium (n=57) 或budesonide/formoterol (n=57).
- 倾向性得分调整和多变量混合效应模型用于控制初级 (FEV1变化) 和二次结果分析中的混因素.
主要成果:
- 所有组都表现出改善,但UMEC/VI表现出优异的结果. 调整后的FEV1平均变化为UMEC/VI的12.6%,对比为tiotropium的8.1%,对比为budesonide/formoterol的5.3% (p<0.001).
- 通过UMEC/VI,运动耐受性 (6分钟步行距离) 和症状控制 (CAT分数减少) 得到了更大的改善.
- 与布德尼德/福莫特罗尔 (29.8%) 相比,UMEC/VI与最低的恶化率 (0.42事件/患者年) 和显著较低的不良事件发生率 (8.8%) 相关.
结论:
- 在稳定中度慢性肺炎患者中,UMEC/VI双重支气管扩展剂治疗似乎与卓越的临床有效性和有利的安全性相关.
- 该研究强调了UMEC/VI在改善肺功能,运动能力和症状负担方面的潜在优势,同时减少恶化.
- 在制定最终的治疗建议之前,需要通过充足的随机对照试验进行进一步的验证.
关键词:
慢性慢性肺炎是一种慢性慢性肺炎,COPD是一种慢性肺炎.双双的支气管扩展器有效性 有效性.安全的安全的安全的安全的安全.在Umeclidinium中使用.维兰特罗尔 (Vilanterol) 是一种更多相关视频
04:03Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
Published on: September 27, 2024
1.3K
07:10Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
10.3K
相关概念视频
01:26COPD: Management Using Bronchodilators and Corticosteroids
709
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
709
01:29Chronic Obstructive Pulmonary Disease-V: Management
3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.1K
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
1.6K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.6K
01:20COPD: Pathogenesis and Clinical Features
1.7K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.7K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K